Market closedNon-fractional
Keros Therapeutics/KROS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
KROS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lexington, United States
Employees
141
Website
www.kerostx.com
KROS Metrics
BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$5.13
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
1.25
Financial strength
Current ratio
24.742
Quick ratio
23.649
Long term debt to equity
2.898
Total debt to equity
3.129
Management effectiveness
Return on assets (TTM)
-25.79%
Return on equity (TTM)
-39.63%
Valuation
Price to revenue (TTM)
5,722.5
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-9.76
Growth
Earnings per share change (TTM)
16.06%
3-year earnings per share growth
29.76%
What the Analysts think about KROS
Analyst Ratings
Majority rating from 10 analysts.
KROS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$43M
7.21%
Profit margin
0.00%
-100.00%
KROS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.27
-$1.33
-$1.34
-$1.21
-
Expected
-$1.34
-$1.35
-$1.37
-$1.35
-$1.24
Surprise
-5.12%
-1.31%
-2.51%
-10.17%
-
KROS News
AllArticlesVideos
![Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth](https://cdn.snapi.dev/images/v1/5/y/biotech32-2496092.jpg)
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Benzinga·1 week ago
![Keros Therapeutics Announces Leadership Updates](https://cdn.snapi.dev/images/v1/w/w/press3-2483001.jpg)
Keros Therapeutics Announces Leadership Updates
GlobeNewsWire·3 weeks ago
![Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association](https://cdn.snapi.dev/images/v1/n/4/press3-2481460.jpg)
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $1.5B as of July 05, 2024.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 0 as of July 05, 2024.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
![Buy or sell Keros Therapeutics stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Keros Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.